Results 201 to 210 of about 244,875 (297)

Mucocutaneous disease activity and damage accrual in systemic lupus erythematosus: analyses from the Asia‐Pacific Lupus Collaboration longitudinal cohort study

open access: yesArthritis Care &Research, Accepted Article.
Objective This research article aims to describe the prevalence, associations and health‐related quality‐of‐life (HRQoL) impact of mucocutaneous features of SLE. Methods Data from the Asia‐Pacific Lupus Collaboration cohort were analysed (2013‐2021). Mucocutaneous activity (MC‐A) items were rash, alopecia and mucosal ulcers; defined by the SLEDAI‐2K ...
Amanda M Saracino   +42 more
wiley   +1 more source

Effects of Causal Beliefs About Gout on Public Views About Gout Management: A Randomized Experimental Study

open access: yesArthritis Care &Research, EarlyView.
Objective Despite well‐described biologic causes, the public views unhealthy lifestyle choices as the primary cause of gout. This study investigated how causal beliefs about gout influence the public's views about its management. Methods In a randomized study, 201 members of the public viewed one of two 2‐minute videos about gout.
Rachel Murdoch   +6 more
wiley   +1 more source

Associations of Rheumatoid Arthritis Disease Activity with Frailty Over Five Years of Follow‐up

open access: yesArthritis Care &Research, Accepted Article.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis registry enrolled from 2003 to 2022 were included. The exposure was RA disease activity measured by Disease Activity Score in 28‐joints (DAS28)
Courtney N. Loecker   +14 more
wiley   +1 more source

Real‐world Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study

open access: yesArthritis Care &Research, Accepted Article.
Objectives Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), yet the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to: 1) identify clinical factors that predict ...
Jay J. Patel   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy